Similar findings have been observed in preclinical models of small-cell lung carcinoma (SCLC) treated with PDL1 antagonists in combination with the CHK1 (mediator of DNA damage response) inhibitor prexasertib [407]. This evidence concerns the gene CD274 and small cell lung carcinoma.